CAR-T Cell Constructs that Recognize CD123 for the Treatment of Acute Myeloid Leukemia

A chimeric antigen receptor-expressing T cell that targets and kills CD123 expressing cancers such as acute myeloid leukemia (AML). The CAR construct works by using a novel anti-CD123 scFv region to enable T cell targeting of CD123 expressing cancer cells and T-cell activation through the incorporation of co-stimulator and intracellular signaling regions. The anti-CD123 CAR-T cell mediated killing of CD123-expressing CHO cells was demonstrated for up to 6 days. CD123 (IL-3 receptor α subunit) is a tumor associated antigen over-expressed on AML blasts and leukemic stem cells. CD123’s low or absent expression on normal hematopoietic stem cells makes it an attractive target for therapy as developers expect fewer adverse side effects.

Contact

Haskell Adler PhD MBA CLP
Senior Licensing Manager
Registered Patent Agent
Haskell.Adler@Moffitt.org
(813) 745-6596

17MA031